Biotricity Q3 FY22 revenue $1.93M (+93% YoY); net loss $7.34M, cash $16.8M

BIOTRICITY INC.

Revenue of $1.93M, up 93% YoY and 7% sequentially; SG&A rose only 40%.
Net loss $7.34M ($0.15/share); adjusted net loss $6.0M ($0.12/share) excluding $1.34M derivative expenses.
Cash position of $16.8M at quarter-end is the highest ever; completed $12M non-dilutive debt financing.
FDA clearance of Biotres expands TAM from $1B to $5.7B; Bioheart direct-to-consumer launched at $199.
Company reiterates expectation for full-year triple-digit revenue growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.